| Formulary Chapter 3: Respiratory system - Full Chapter
|
| 03.03 |
Cromoglicate, related therapy and leukotriene receptor antagonists |
|
|
| 03.03.01 |
Cromoglicate and related therapy |
|
|
| 03.03.02 |
Leukotriene receptor antagonists |
|
|
| 03.03.03 |
Phosphodiesterase type-4 inhibitors |
|
|
Montelukast (Singulair® )
(Oral presentations)
 
|
Non Formulary
|
Use in line with recommendations in BTS-SIGN asthma guideline |
Nedocromil (Tilade® CFC-free inhaler)
|
Non Formulary
|
|
Sodium Cromoglicate
(Oral presentations)
|
Non Formulary
|
|
Sodium Cromoglicate (Comogen Easi-Breathe®)
|
Non Formulary
|
|
Sodium Cromoglicate (Intal®)
|
Non Formulary
|
|
Zafirlukast
(tablets)
|
Non Formulary
|
- Accolate® brand discontinued March 2018
- No other generics available within UK
|
Key |
 |
Restricted Drug |
 |
Unlicensed |
|
|
Link to adult BNF
|
|
|
Link to children's BNF
|
|
|
Link to SPCs
|
|
Cytotoxic Drug |
|
Controlled Drug |
|
|
High Cost Medicine |
|
Cancer Drugs Fund |
|
NHS England |
|
Homecare |
|
ICB |
|
Low carbon footprint |
|
Medium carbon footprint |
|
High carbon footprint |
|
| Status |
Description |
|
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications |
|
Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry. |
|
Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry. |
|
Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist. |
|
Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only |
|
Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information. |
|
Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use. |
|
Check Notes as varies across the area |
|
|
